Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the use of dermatoscopy and videodermatoscopy in therapeutic follow-up, noting that videodermatoscopy is a reliable tool despite potential cost issues with high magnifications.

This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This study showed that in C3H/HeJ mice, focal follicular inflammation starts before overt hair loss, with inflammation severity possibly reaching a threshold causing hair follicle dystrophy prior to visible hair loss.

This review discusses neutrophil-associated and infiltrative scarring alopecias, as well as promising new treatments, but reports no new clinical results.

This article reviews the role of vasoactive intestinal peptide in maintaining immune privilege in hair follicles and does not report new findings; the authors propose it as essential for immune homeostasis in alopecia areata.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

This review discusses evidence-based treatments for common hair loss forms, noting robust support for androgenetic alopecia therapies but limited long-term data and fewer high-quality studies for alopecia areata and cicatricial alopecias.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

This study found that T-regulatory cells, specifically the FOXP3 CD39 subset, were significantly reduced in both circulation and hair follicles of alopecia areata patients compared to healthy subjects, suggesting potential therapeutic targets.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.

This study found that androgenic alopecia at an early age was associated with a lower risk of prostate cancer, contrary to assumptions about androgens' role.

In this NIH study, female donor to male recipient sex mismatch was significantly associated with the development of vitiligo and/or alopecia areata in patients with chronic graft-vs-host disease.

The authors concluded that intralesional triamcinolone acetonide may benefit patients with patch-type alopecia areata, but the evidence is limited due to small, bias-prone studies with variations in treatment protocols.

This report describes the unexpected development of alopecia areata in kidney-pancreas transplant recipients undergoing cyclosporine-based immunosuppressive therapy, suggesting a complex relationship between the treatment and disease.

This review discusses rodent models of alopecia areata and suggests they are crucial for understanding the autoimmune mechanisms and potential treatments but reports no new clinical results.

Early stage bald spots are linked to skin inflammation and damage to the upper part of the hair follicle.

This study found no significant difference in serum and hair levels of iron, zinc, and copper between female alopecia areata patients and healthy controls.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this study, ustekinumab did not promote hair regrowth in human patients with alopecia areata or prevent disease development in an AA mouse model, suggesting limited efficacy for this treatment.

This study highlights the significant psychological impact of alopecia areata, emphasizing the reciprocal relationship between the disorder and psychiatric issues, and underscores the importance of identifying patients needing additional psychological support, especially women, young individuals, and those with severe alopecia or previous psychiatric history.

This study found distinct gene expression patterns in the blood of alopecia areata patients, suggesting involvement of immune processes and new pathways like Wnt signaling and apoptosis in disease pathogenesis.

This study provided the first proteome dataset for alopecia areata, revealing novel pathways in the disease mechanisms that may lead to new therapeutic targets.

This study reports that horizontal sections of scalp biopsies improve the diagnosis of alopecia areata, especially when characteristic inflammatory infiltrates are missing.

This study found that Th17 lymphocytes may play a more crucial role than cytotoxic T cells in the development of alopecia areata due to their infiltration around the hair bulb/bulge, which exacerbates hair loss as histopathological grade worsens.

This study reports that sequential high- and low-dose prednisolone therapy effectively promotes complete hair regrowth in 62% of children with severe alopecia areata, while minimizing severe side effects.